CN101181336A - A method for refining the effective part of bitter gourd for lowering blood sugar - Google Patents
A method for refining the effective part of bitter gourd for lowering blood sugar Download PDFInfo
- Publication number
- CN101181336A CN101181336A CNA2007101584965A CN200710158496A CN101181336A CN 101181336 A CN101181336 A CN 101181336A CN A2007101584965 A CNA2007101584965 A CN A2007101584965A CN 200710158496 A CN200710158496 A CN 200710158496A CN 101181336 A CN101181336 A CN 101181336A
- Authority
- CN
- China
- Prior art keywords
- blood sugar
- refining
- bitter gourd
- momordica
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008280 blood Substances 0.000 title claims abstract description 86
- 210000004369 blood Anatomy 0.000 title claims abstract description 86
- 235000000346 sugar Nutrition 0.000 title claims abstract description 67
- 235000009811 Momordica charantia Nutrition 0.000 title claims abstract description 60
- 238000000034 method Methods 0.000 title claims abstract description 44
- 235000008322 Trichosanthes cucumerina Nutrition 0.000 title claims abstract description 34
- 238000007670 refining Methods 0.000 title claims abstract description 18
- 244000078912 Trichosanthes cucumerina Species 0.000 title claims 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 93
- 239000003814 drug Substances 0.000 claims abstract description 34
- 239000011347 resin Substances 0.000 claims abstract description 33
- 229920005989 resin Polymers 0.000 claims abstract description 33
- 238000010992 reflux Methods 0.000 claims abstract description 13
- 239000007788 liquid Substances 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 239000003826 tablet Substances 0.000 claims abstract description 9
- 239000006187 pill Substances 0.000 claims abstract description 6
- 239000002775 capsule Substances 0.000 claims abstract description 5
- 239000008187 granular material Substances 0.000 claims abstract description 4
- 238000010521 absorption reaction Methods 0.000 claims abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 32
- 229940079593 drug Drugs 0.000 claims description 19
- 238000000746 purification Methods 0.000 claims description 7
- 239000000395 magnesium oxide Substances 0.000 claims description 4
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 4
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical group [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 4
- 238000010828 elution Methods 0.000 claims description 3
- 239000008188 pellet Substances 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000006189 buccal tablet Substances 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- -1 suspensoid Substances 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 239000007854 depigmenting agent Substances 0.000 claims 4
- 230000001476 alcoholic effect Effects 0.000 claims 3
- 239000000470 constituent Substances 0.000 claims 2
- 229940023488 pill Drugs 0.000 claims 2
- 230000000274 adsorptive effect Effects 0.000 claims 1
- 229940046011 buccal tablet Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 239000007903 gelatin capsule Substances 0.000 claims 1
- 238000010298 pulverizing process Methods 0.000 claims 1
- 238000001291 vacuum drying Methods 0.000 claims 1
- 235000009815 Momordica Nutrition 0.000 abstract description 57
- 241000218984 Momordica Species 0.000 abstract description 57
- 244000302512 Momordica charantia Species 0.000 abstract description 50
- 239000000284 extract Substances 0.000 abstract description 30
- 239000012141 concentrate Substances 0.000 abstract description 11
- 238000004042 decolorization Methods 0.000 abstract description 8
- 238000001179 sorption measurement Methods 0.000 abstract description 6
- 239000004480 active ingredient Substances 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 239000003960 organic solvent Substances 0.000 abstract description 2
- 238000000638 solvent extraction Methods 0.000 abstract description 2
- 239000000725 suspension Substances 0.000 abstract description 2
- 238000005516 engineering process Methods 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 53
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 36
- 230000002218 hypoglycaemic effect Effects 0.000 description 36
- 239000000463 material Substances 0.000 description 27
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 24
- 239000008103 glucose Substances 0.000 description 24
- 229930182470 glycoside Natural products 0.000 description 24
- 150000002338 glycosides Chemical class 0.000 description 24
- 230000000694 effects Effects 0.000 description 22
- 206010012601 diabetes mellitus Diseases 0.000 description 20
- 201000001421 hyperglycemia Diseases 0.000 description 18
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 18
- 229930182478 glucoside Natural products 0.000 description 17
- 150000008131 glucosides Chemical class 0.000 description 17
- 239000003480 eluent Substances 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 12
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 12
- 238000000605 extraction Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 241000283973 Oryctolagus cuniculus Species 0.000 description 11
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 10
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 10
- 229960001052 streptozocin Drugs 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 102000004877 Insulin Human genes 0.000 description 9
- 108090001061 Insulin Proteins 0.000 description 9
- 239000012535 impurity Substances 0.000 description 9
- 229940125396 insulin Drugs 0.000 description 9
- 235000009812 Momordica cochinchinensis Nutrition 0.000 description 7
- 235000018365 Momordica dioica Nutrition 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 4
- 229930002534 steroid glycoside Natural products 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 150000008143 steroidal glycosides Chemical class 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229960004580 glibenclamide Drugs 0.000 description 2
- 229930182480 glucuronide Natural products 0.000 description 2
- 150000008134 glucuronides Chemical class 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000012716 precipitator Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 229910018072 Al 2 O 3 Inorganic materials 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 235000011869 dried fruits Nutrition 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000667 effect on insulin Effects 0.000 description 1
- 238000005485 electric heating Methods 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 239000009384 kangtai Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 238000009101 premedication Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属于医药技术领域,公开了一种苦瓜降血糖有效部位的精制方法,(1)制备脱色精制前的苦瓜药液:将苦瓜饮片干燥、粉碎,用乙醇回流提取,浓缩得浸膏;将浸膏稀释,上大孔吸附树脂柱吸附,洗涤,再用乙醇溶液洗脱,得到脱色精制前的苦瓜药液。(2)精制过程:收集树脂柱的乙醇洗脱液,加入脱色剂,加热回流,滤过,减压浓缩,真空干燥,即得苦瓜甾苷。本发明提取的苦瓜甾苷可以直接制成各种制剂,如片剂、胶囊剂、颗粒剂、口服液、丸剂、混悬剂、滴丸剂、巴布剂、贴剂等。本发明与传统工艺相比,具有体积小、不吸潮、有效成分含量高的特点。与溶剂萃取法相比,工艺流程中不使用毒性易挥发的有机溶剂、安全可靠,生产成本低,对环境无污染。The invention belongs to the technical field of medicine, and discloses a method for refining the effective part of bitter melon for lowering blood sugar. (1) preparing bitter melon medicinal liquid before decolorization and refining: dry and pulverize bitter melon decoction pieces, extract with ethanol reflux, and concentrate to obtain extract; The extract is diluted, adsorbed on a macroporous adsorption resin column, washed, and then eluted with ethanol solution to obtain the bitter gourd liquid before decolorization and refining. (2) Refining process: collect the ethanol eluate from the resin column, add a decolorizer, heat to reflux, filter, concentrate under reduced pressure, and dry in vacuum to obtain Momordica charantrin. The Momordica charantrin extracted in the present invention can be directly made into various preparations, such as tablets, capsules, granules, oral liquids, pills, suspensions, dropping pills, cataplasms, patches and the like. Compared with the traditional technology, the invention has the characteristics of small volume, no moisture absorption and high active ingredient content. Compared with the solvent extraction method, no toxic and volatile organic solvents are used in the process, which is safe and reliable, with low production cost and no pollution to the environment.
Description
技术领域technical field
本发明属于医药技术领域,涉及一种苦瓜降血糖有效部位(KGE)的精制方法,具体是涉及苦瓜中一种降血糖有效部位甾苷类成分的精制方法。The invention belongs to the technical field of medicines, and relates to a method for refining bitter melon effective fractions (KGE) for lowering blood sugar, in particular to a method for refining steroidal components of effective fractions for lowering blood sugar in bitter melon.
背景技术Background technique
苦瓜为传统中药,古方中多有记载。近年来的国内外研究及大量文献报道显示,苦瓜具有持续、高效的降血糖作用,且没有任何毒副反应。苦瓜中含有的活性成分不仅能够通过促进β-细胞分泌胰岛素来调节血糖,同时还具有胰岛素样作用,且口服疗效确切。将其开发成治疗II型糖尿病的高效、低毒、廉价的现代中药制剂,具有广阔的市场前景。Bitter gourd is a traditional Chinese medicine, and there are many records in ancient prescriptions. In recent years, domestic and foreign studies and a large number of literature reports have shown that bitter melon has a sustained and efficient hypoglycemic effect without any toxic and side effects. The active ingredients contained in bitter melon can not only regulate blood sugar by promoting the secretion of insulin by β-cells, but also have insulin-like effects, and the oral curative effect is definite. Developing it into a highly efficient, low-toxic, and cheap modern Chinese medicine preparation for treating type II diabetes has broad market prospects.
目前制备苦瓜甾苷类成分的方法主要有水煎煮法、醇沉法、大孔吸附树脂法等提取工艺。上述工艺存在杂质多,有效成分含量低,含有大量糖类,并含有一定易吸潮成份,影响药效和产品质量。At present, the methods for preparing bitter melon steroids mainly include extraction processes such as water decoction, alcohol precipitation, and macroporous adsorption resin. The above-mentioned process has many impurities, low active ingredient content, a large amount of sugar, and certain moisture-absorbing ingredients, which affect the efficacy and product quality.
发明内容Contents of the invention
本发明要解决的技术问题,是提供一种苦瓜中降血糖有效部位甾苷类成分的精制方法。The technical problem to be solved by the present invention is to provide a method for refining the steroidal glycoside components in the effective hypoglycemic part of the bitter gourd.
采用的技术方案是:The technical solutions adopted are:
1、制备脱色精制前的苦瓜药液:将苦瓜饮片干燥、粉碎,用10-95%乙醇回流提取,回收乙醇,浓缩得浸膏;将浸膏加水稀释,上大孔吸附树脂柱吸附,用pH2-8的水洗涤,弃去水洗脱液,再用5%-95%乙醇溶液洗脱,洗脱5-20倍树脂柱体积,得到脱色精制前的苦瓜药液。1. Prepare bitter gourd medicinal liquid before decolorization and refining: dry and pulverize bitter gourd decoction pieces, extract with 10-95% ethanol under reflux, recycle ethanol, and concentrate to obtain extract; dilute the extract with water, absorb on a macroporous adsorption resin column, and use Washing with water with a pH of 2-8, discarding the water eluent, and then eluting with 5%-95% ethanol solution for 5-20 times the volume of the resin column to obtain the bitter melon liquid before decolorization and purification.
2、精制过程:收集树脂柱的乙醇洗脱液,按洗脱液体积0.1-50%加入脱色剂,加热回流0.1-10小时,滤过,减压浓缩,真空干燥,即得苦瓜甾苷。调节树脂柱的洗脱体积,使其既能将甾苷类成分洗脱完全,洗脱液中药物的浓度又适合脱色处理,两个步骤衔接紧密。2. Refining process: collect the ethanol eluate from the resin column, add a decolorizer according to the volume of the eluent at 0.1-50%, heat and reflux for 0.1-10 hours, filter, concentrate under reduced pressure, and dry in vacuum to obtain Momordica charantrin. The elution volume of the resin column is adjusted so that the steroidal glycosides can be completely eluted, and the concentration of the drug in the eluate is suitable for decolorization, so that the two steps are closely connected.
采用本法苦瓜降血糖有效部位中苦瓜甾苷含量可达50%以上。The content of momordica glycosides in the effective part of the bitter gourd for lowering blood sugar by the method can reach more than 50%.
本发明提取的苦瓜甾苷可以直接制成各种制剂,如片剂、胶囊剂、颗粒剂、口服液、丸剂、混悬剂、滴丸剂、微丸剂、口含片、胶丸、软胶囊、喷雾剂、气雾剂、巴布剂、贴剂等,为实现中药现代化提供了一条新的途径。The Momordica charantrin extracted in the present invention can be directly made into various preparations, such as tablets, capsules, granules, oral liquids, pills, suspensions, dropping pills, micropills, buccal tablets, capsules, soft capsules, Sprays, aerosols, cataplasms, patches, etc. provide a new way to realize the modernization of traditional Chinese medicine.
本发明的苦瓜甾苷提取精制工艺与传统工艺相比,有以下3个优点:Compared with the traditional process, the Momordica glucoside extraction and refining process of the present invention has the following three advantages:
1、缩小剂量,提高中药内在质量和制剂水平。苦瓜乙醇提取物经大孔吸附树脂(RAT)和脱色处理后得到的精制物可使药效成分高度富集,杂质少,提取率仅为原生药的1-5%(水煎法为20-30%左右,醇沉法为15%左右),有利于制成现代剂型的中药,也便于质量控制。1. Reduce the dose, improve the internal quality and preparation level of traditional Chinese medicine. The refined product obtained after the ethanol extract of bitter gourd is processed by macroporous adsorption resin (RAT) and decolorization can make the medicinal ingredients highly enriched, with few impurities, and the extraction rate is only 1-5% of the original drug (the decoction method is 20- About 30%, alcohol precipitation method is about 15%), is conducive to making the traditional Chinese medicine of modern dosage form, is also convenient for quality control.
2、减小产品的吸潮性。传统工艺制备的中成药大部分具有较强的吸潮性,是中药生产及贮藏中长期存在的难题。而经RAT和脱色处理后,可有效地去除提取物中大量的糖类、无机盐、黏液质等吸潮成分,有利于多种中药剂型的生产,增强产品的稳定性。2. Reduce the moisture absorption of the product. Most of the traditional Chinese patent medicines have strong hygroscopicity, which is a long-standing problem in the production and storage of traditional Chinese medicines. However, after RAT and decolorization treatment, it can effectively remove a large amount of moisture-absorbing components such as sugars, inorganic salts, and mucus in the extract, which is beneficial to the production of various traditional Chinese medicine forms and enhances the stability of the product.
3、改善制剂外观颜色,提高有效成分含量。RAT的乙醇洗脱液中加入某种脱色剂加热回流处理后,所得苦瓜甾苷的颜色为淡黄色或黄色,与脱色前的黄棕色或棕色相比更易于被接受,同时也进一步提高了苦瓜降血糖有效部位中苦瓜甾苷的含量。3. Improve the appearance and color of the preparation, and increase the content of active ingredients. After adding a certain decolorizing agent to the ethanol eluent of RAT and heating to reflux, the color of the obtained Momordica glycosides is light yellow or yellow, which is more acceptable than the yellowish brown or brown before decolorization, and also further improves the quality of Momordica charantia. The content of Momordica glycosides in effective fractions for lowering blood sugar.
经本工艺提取精制所得有效部位体积小、不吸潮、颜色浅,容易制成外型美观的各种剂型,尤其适用于颗粒剂、胶囊剂和片剂,使中药的粗、大、黑制剂升级换代为现代制剂。The effective parts extracted and refined by this process are small in size, non-moisture-absorbing, and light in color, and can be easily made into various dosage forms with beautiful appearance, especially suitable for granules, capsules and tablets, making the thick, large and black preparations of traditional Chinese medicine Upgrading to modern formulations.
经本工艺提取精制所得的苦瓜甾苷对不同原因所致的不同动物模型的高血糖均有一定程度的降糖作用,并且其降糖作用有的与阳性对照药物相当甚至更强。The Momordica glycoside extracted and refined by this process has a certain degree of hypoglycemic effect on hyperglycemia in different animal models caused by different reasons, and some of its hypoglycemic effects are comparable to or even stronger than positive control drugs.
本发明与传统的溶剂萃取法相比,工艺简单,工艺流程中不使用毒性易挥发的有机溶剂、安全可靠,生产成本低,对环境无污染。Compared with the traditional solvent extraction method, the invention has simple process, does not use toxic and volatile organic solvents in the process flow, is safe and reliable, has low production cost, and has no pollution to the environment.
具体实施方式Detailed ways
一、苦瓜降血糖有效部位的精制方法1. Refining method of effective part of bitter gourd for lowering blood sugar
实施例1Example 1
原料采用去除杂质的苦瓜,经干燥、粉碎,用90%乙醇回流提取2次,每次用量为生药材重量的7、5倍,提取时间为2、1小时,合并提取液,过滤,回收乙醇,浓缩得浸膏,将浸膏加水稀释至原药材的15倍体积,上树脂柱吸附,原药材与树脂的重量比是1∶3,用水洗涤、50%乙醇溶液洗脱15个树脂柱体积,收集乙醇洗脱液,按洗脱液体积10%加入活性炭,加热回流2小时,滤过,减压浓缩,真空干燥,即得苦瓜甾苷。采用本法苦瓜降血糖有效部位中苦瓜甾苷含量可达50%以上。还可以用5%乙醇溶液洗脱。The raw material is balsam pear with impurities removed, dried and crushed, and refluxed with 90% ethanol to extract twice, each time the amount is 7 or 5 times the weight of the raw medicinal material, the extraction time is 2 or 1 hour, the extracts are combined, filtered, and the ethanol is recovered , concentrated to get the medicinal extract, the medicinal extract is diluted with water to 15 times the volume of the original medicinal material, and adsorbed on a resin column. The weight ratio of the original medicinal material and resin is 1: 3, washed with water, and eluted with 50% ethanol solution for 15 resin column volumes , collect the ethanol eluent, add activated carbon according to the volume of the eluent at 10%, heat to reflux for 2 hours, filter, concentrate under reduced pressure, and dry in vacuum to obtain Momordica charantrin. The content of momordica glycosides in the effective part of the bitter gourd for lowering blood sugar by the method can reach more than 50%. It can also be eluted with 5% ethanol solution.
实施例2Example 2
原料采用去除杂质的苦瓜,经干燥、粉碎,用70%乙醇回流提取2次,每次用量为生药材重量的8、6倍,提取时间为2、2小时,合并提取液,过滤,回收乙醇,浓缩得浸膏,将浸膏加水稀释至原药材的25倍体积,上树脂柱吸附,原药材与树脂的重量比是1∶5,用水洗涤、70%乙醇溶液洗脱20个树脂柱体积,收集乙醇洗脱液,按洗脱液体积7%加入活性炭,超声处理1.5小时,滤过,减压浓缩,真空干燥,即得苦瓜甾苷。采用本法苦瓜降血糖有效部位中苦瓜甾苷含量可达50%以上。The raw material is balsam pear that removes impurities, dried and crushed, and refluxed with 70% ethanol to extract twice, each time the amount is 8 or 6 times the weight of the raw medicinal material, the extraction time is 2 or 2 hours, the extracts are combined, filtered, and the ethanol is recovered , concentrated to obtain medicinal extract, the medicinal extract is diluted with water to 25 times the volume of the original medicinal material, and adsorbed on a resin column. The weight ratio of the original medicinal material and resin is 1: 5, washed with water, and eluted with 70% ethanol solution for 20 resin column volumes , collect the ethanol eluent, add activated carbon according to the volume of the eluent at 7%, ultrasonicate for 1.5 hours, filter, concentrate under reduced pressure, and dry in vacuum to obtain Momordica charantrin. The content of momordica glycosides in the effective part of the bitter gourd for lowering blood sugar by the method can reach more than 50%.
实施例3Example 3
原料采用去除杂质的苦瓜,经干燥、粉碎,用70%乙醇回流提取2次,每次用量为生药材重量的10、8倍,提取时间为2、1小时,合并提取液,过滤,回收乙醇,浓缩得浸膏,将浸膏加水稀释至原药材的25倍体积,上树脂柱吸附,原药材与树脂的重量比是1∶5,用水洗涤、70%乙醇溶液洗脱20个柱体积,收集乙醇洗脱液,按洗脱液体积7%加入硅藻土,加热回流2小时,滤过,减压浓缩,真空干燥,即得苦瓜甾苷。采用本法苦瓜降血糖有效部位中苦瓜甾苷含量可达50%以上。The raw material is balsam pear with impurities removed, dried and crushed, and refluxed with 70% ethanol to extract twice, each dosage is 10 or 8 times the weight of raw medicinal materials, and the extraction time is 2 or 1 hour. Combine the extracts, filter, and recover ethanol , concentrated to obtain medicinal extract, the medicinal extract is diluted with water to 25 times the volume of the original medicinal material, and adsorbed on a resin column. The weight ratio of the original medicinal material and resin is 1: 5, washed with water, and eluted with 70% ethanol solution for 20 column volumes, Collect the ethanol eluent, add diatomaceous earth according to the volume of the eluent at 7%, heat to reflux for 2 hours, filter, concentrate under reduced pressure, and dry in vacuo to obtain Momordica charantrin. The content of momordica glycosides in the effective part of the bitter gourd for lowering blood sugar by the method can reach more than 50%.
实施例4Example 4
原料采用去除杂质的苦瓜,经干燥、粉碎,用95%乙醇回流提取2次,每次用量为生药材重量的8、6倍,提取时间为2、1小时,合并提取液,过滤,回收乙醇,浓缩得浸膏,将浸膏加水稀释至原药材的20倍体积,上树脂柱吸附,原药材与树脂的重量比是1∶3,用水洗涤、90%乙醇溶液洗脱12个树脂柱体积,收集乙醇洗脱液,按洗脱液体积7%加入Al2O3,超声处理1.5小时,滤过,减压浓缩,真空干燥,即得苦瓜甾苷。采用本法苦瓜甾苷降血糖有效部位中苦瓜甾苷含量可达50%以上。The raw material is balsam pear with impurities removed, dried and crushed, and refluxed with 95% ethanol to extract twice, each time the amount is 8 or 6 times the weight of the raw medicinal material, the extraction time is 2 or 1 hour, the extracts are combined, filtered, and the ethanol is recovered , concentrated to obtain medicinal extract, the medicinal extract is diluted with water to 20 times the volume of the original medicinal material, and adsorbed on a resin column. The weight ratio of the original medicinal material and resin is 1: 3, washed with water, and eluted with 90% ethanol solution for 12 resin column volumes , collect the ethanol eluent, add Al 2 O 3 according to the volume of the eluent at 7%, ultrasonicate for 1.5 hours, filter, concentrate under reduced pressure, and dry in vacuo to obtain Momordica charantrin. The content of Momordica glucoside in the active parts of Momordica glucoside for lowering blood sugar by this method can reach more than 50%.
实施例5Example 5
原料采用去除杂质的苦瓜,经干燥、粉碎,用90%乙醇回流提取2次,每次用量为生药材重量的8、8倍,提取时间为2、1小时,合并提取液,过滤,回收乙醇,浓缩得浸膏,将浸膏加水稀释至原药材的15倍体积,上树脂柱吸附,原药材与树脂的重量比是1∶4,用水洗涤、90%乙醇溶液洗脱15个树脂柱体积,收集乙醇洗脱液,按洗脱液体积10%加入氧化镁,加热回流1小时,滤过,减压浓缩,真空干燥,即得苦瓜甾苷。采用本法苦瓜降血糖有效部位中苦瓜甾苷含量可达50%以上。The raw material is balsam pear with impurities removed, dried and crushed, and refluxed with 90% ethanol to extract twice, each dosage is 8 or 8 times the weight of raw medicinal materials, and the extraction time is 2 or 1 hour. The extracts are combined, filtered, and the ethanol is recovered , concentrated to get the medicinal extract, the medicinal extract is diluted with water to 15 times the volume of the original medicinal material, and adsorbed on a resin column. The weight ratio of the original medicinal material and resin is 1: 4, washed with water, and eluted with 90% ethanol solution for 15 resin column volumes , collect the ethanol eluate, add magnesium oxide according to the volume of the eluent at 10%, heat to reflux for 1 hour, filter, concentrate under reduced pressure, and dry in vacuo to obtain Momordica charantrin. The content of momordica glycosides in the effective part of the bitter gourd for lowering blood sugar by the method can reach more than 50%.
实施例6Example 6
原料采用去除杂质的苦瓜,经干燥、粉碎,用70%乙醇回流提取2次,每次用量为生药材重量的8、6倍,提取时间为2、2小时,合并提取液,过滤,回收乙醇,浓缩得浸膏,将浸膏加水稀释至原药材的15倍体积,上树脂柱吸附,原药材与树脂的重量比是1∶7,用水洗涤、70%乙醇溶液洗脱20个树脂柱体积,收集乙醇洗脱液,按洗脱液体积的5%加入氧化镁,80℃保温处理4小时,滤过,减压浓缩,真空干燥,即得苦瓜甾苷。采用本法苦瓜降血糖有效部位中苦瓜甾苷含量可达50%以上。The raw material is balsam pear that removes impurities, dried and crushed, and refluxed with 70% ethanol to extract twice, each time the amount is 8 or 6 times the weight of the raw medicinal material, the extraction time is 2 or 2 hours, the extracts are combined, filtered, and the ethanol is recovered , concentrated to get the medicinal extract, the medicinal extract is diluted with water to 15 times the volume of the original medicinal material, and adsorbed on a resin column. The weight ratio of the original medicinal material and resin is 1: 7, washed with water, and eluted with 70% ethanol solution for 20 resin column volumes , collect the ethanol eluent, add magnesium oxide according to 5% of the volume of the eluent, heat it at 80°C for 4 hours, filter, concentrate under reduced pressure, and dry in vacuum to obtain Momordica charantrin. The content of momordica glycosides in the effective part of the bitter gourd for lowering blood sugar by the method can reach more than 50%.
实施例7Example 7
原料采用去除杂质的苦瓜,经干燥、粉碎,用70%乙醇回流提取2次,每次用量为生药材重量的8、6倍,提取时间为2、2小时,合并提取液,过滤,回收乙醇,浓缩得浸膏,将浸膏加水稀释至原药材的15倍体积,上树脂柱吸附,原药材与树脂的重量比是1∶7,用水洗涤、90%乙醇溶液洗脱20个树脂柱体积,收集乙醇洗脱液,按洗脱液体积的10%加入氧化镁,80℃保温处理4小时,滤过,减压浓缩,真空干燥,即得苦瓜甾苷。采用本法苦瓜降血糖有效部位中苦瓜甾苷含量可达50%以上。The raw material is balsam pear that removes impurities, dried and crushed, and refluxed with 70% ethanol to extract twice, each time the amount is 8 or 6 times the weight of the raw medicinal material, the extraction time is 2 or 2 hours, the extracts are combined, filtered, and the ethanol is recovered , concentrated to obtain medicinal extract, the medicinal extract is diluted with water to 15 times the volume of the original medicinal material, and adsorbed on a resin column. The weight ratio of the original medicinal material and resin is 1: 7, washed with water, and eluted with 90% ethanol solution for 20 resin column volumes , collect the ethanol eluent, add magnesium oxide according to 10% of the volume of the eluent, heat it at 80° C. for 4 hours, filter, concentrate under reduced pressure, and dry in vacuum to obtain Momordica charantrin. The content of momordica glycosides in the effective part of the bitter gourd for lowering blood sugar by the method can reach more than 50%.
二、精制后的苦瓜甾苷的降血糖效果2. The hypoglycemic effect of refined Momordica glycosides
实例例8Example 8
(一)对葡萄糖性小鼠、链脲霉素及四氧嘧啶所致糖尿病小鼠高血糖的降血糖作用(1) Hypoglycemic effect on hyperglycemia induced by glucose mice, streptozotocin and alloxan in diabetic mice
1 试验材料1 Test material
1.1仪器:7230分光光度计(上海分析仪器厂)、80-2离心沉淀器(上海手术器械厂)、DK-98-I电子恒温水浴锅(天津市泰斯特仪器有限公司)、可调微量移液管(10-50ul),(上海亚荣生化仪器厂)、可调定量加液器(上海求精玻璃仪器厂)、GT-1640超级血糖测试仪(日本京都)。1.1 Instruments: 7230 Spectrophotometer (Shanghai Analytical Instrument Factory), 80-2 Centrifugal Precipitator (Shanghai Surgical Instrument Factory), DK-98-I Electronic Constant Temperature Water Bath (Tianjin Test Instrument Co., Ltd.), adjustable trace Pipette (10-50ul), (Shanghai Yarong Biochemical Instrument Factory), adjustable dosing device (Shanghai Qiujing Glass Instrument Factory), GT-1640 super blood glucose tester (Kyoto, Japan).
1.2药材与试剂:苦瓜药材干品购于广州,经辽宁中医药大学植物教研室王冰教授鉴定为葫芦科苦瓜属植物苦瓜(Momordica Charantia L.)的干燥果实;苦瓜甾苷由上述苦瓜药材经本课题组提取纯化制得(总甾苷含量大于50%)。链脲霉素(Sigma公司,北京分装,规格100mg);四氧嘧啶(Fluka公司生产):葡萄糖试剂盒(北京北化康泰临床试剂有限公司,批号050508);降糖灵(天津太平洋制药有限公司,批号030809);葡萄糖(沈阳化学试剂厂,批号20010306);血糖试纸(日本产)上海易维经贸发展有限公司总经销;柱层析硅胶、薄层层析硅胶G为青岛海洋化工厂产品,其他试剂均为分析纯。1.2 Medicinal materials and reagents: The dry bitter melon medicinal material was purchased in Guangzhou, and was identified as the dried fruit of Momordica Charantia L. by Professor Wang Bing of the Botanical Teaching and Research Office of Liaoning University of Traditional Chinese Medicine; Momordica Charantia L. The subject group extracts and purifies it (total steroid glycoside content is greater than 50%). Streptozotocin (Sigma Company, Beijing subpackaging, specification 100mg); Alloxan (produced by Fluka Company): glucose kit (Beijing Beihua Kangtai Clinical Reagent Co., Ltd., batch number 050508); Jiangtangling (Tianjin Pacific Pharmaceutical Co., Ltd., Batch No. 030809); glucose (Shenyang Chemical Reagent Factory, batch No. 20010306); blood glucose test strips (made in Japan) general distributor of Shanghai Yiwei Economic and Trade Development Co., Ltd.; column chromatography silica gel and TLC silica gel G are products of Qingdao Ocean Chemical Factory, others Reagents were all analytically pure.
1.3动物:健康昆明种小白鼠,体重23±1g,由辽宁中医药大学动物实验中心提供,许可证:SCX(辽)2004-0018。各组动物均在同样环境下饮水、摄食、保持自然光照。温度25℃,湿度60-70%。颗粒饲料由沈阳市于洪区动物实验饲料厂提供。1.3 Animals: healthy Kunming mice, weighing 23±1g, provided by the Animal Experiment Center of Liaoning University of Traditional Chinese Medicine, license: SCX (Liao) 2004-0018. Animals in each group were given water, food, and natural light in the same environment. The temperature is 25°C and the humidity is 60-70%. Pellet feed was provided by Animal Experimental Feed Factory in Yuhong District, Shenyang City.
2 方法2 methods
2.1苦瓜甾苷的制备:取苦瓜药材,用70%乙醇回流提取3次。合并滤液,通过D-101大孔吸附树脂柱,用水洗至无色,然后用70%乙醇洗脱,收集乙醇洗脱液,脱色,过滤,滤液减压浓缩,得苦瓜甾苷。经比色测定,苦瓜甾苷的含量为55.2%。2.1 Preparation of Momordica charantia glycosides: take Momordica charantia medicinal material, and reflux extraction with 70% ethanol for 3 times. The filtrates were combined, passed through a D-101 macroporous adsorption resin column, washed with water until colorless, and then eluted with 70% ethanol. The ethanol eluate was collected, decolorized, filtered, and the filtrate was concentrated under reduced pressure to obtain Momordica glycosides. As determined by colorimetry, the content of Momordica glycosides was 55.2%.
2.2苦瓜甾苷对葡萄糖性小鼠高血糖的影响:取健康小鼠50只,雌雄各半,饲养3d后,随机分为5组(对照组、模型组、大剂量组、小剂量组、降糖灵组),每组10只。于实验前禁食不禁水,12h后,灌胃给药。大、小剂量组分别给予苦瓜甾苷200、100mg/kg,降糖灵组给予降糖灵100mg/kg,对照与模型组给予同体积蒸馏水。30min后各组分别灌胃给予葡萄糖溶液4.0g/kg,对照组给予同体积的蒸馏水。在给药后60、120min时,分别从小鼠眶静脉窦取血,血样离心(3000rpm/10min),分离血清,按葡萄糖试剂盒说明书操作测定血糖含量。实验结果经统计学分析选用t检验法,比较各给药组与模型组之间的差异。2.2 Effect of Momordica charantrin on hyperglycemia in glucose-induced mice: Take 50 healthy mice, half male and half male, and after feeding for 3 days, they were randomly divided into 5 groups (control group, model group, high-dose group, low-dose group, Jiangtangling group), 10 per group. Before the experiment, they were fasted without water, and 12 hours later, they were administered by intragastric administration. The high-dose and low-dose groups were given Momordica glycosides 200 and 100 mg/kg respectively, the Jiangtangling group was given Jiangtangling 100 mg/kg, and the control and model groups were given the same volume of distilled water. After 30 minutes, each group was given glucose solution 4.0g/kg by intragastric administration, and the control group was given the same volume of distilled water. At 60 and 120 minutes after the administration, blood was collected from the orbital sinus of the mice, and the blood samples were centrifuged (3000 rpm/10 min) to separate the serum, and the blood sugar content was measured according to the instructions of the glucose kit. The experimental results were statistically analyzed using the t-test method to compare the differences between each administration group and the model group.
2.3苦瓜甾苷对链脲霉素所致糖尿病小鼠高血糖的影响:选合格小鼠92只(雄性),饲养3d后,取12只为对照组,腹腔注射生理盐水,其余80只腹腔注射链脲霉素150mg/kg,72h后测试小鼠空腹血糖含量,取血糖值在16-24mmol/L之间小鼠,按血糖含量高低分为4组(模型组、大剂量组、小剂量组、降糖灵组)每组12只。大、小剂量组分别灌胃给予苦瓜甾苷200、100mg/kg,降糖灵组给予降糖灵100mg/kg,对照组及模型组给予同体积的蒸馏水。每日灌胃一次,连续给药14d。在给药后3、7、14d时分别测试小鼠血糖含量,小鼠测血糖前禁食12h,测试时把小鼠放入玻璃钟罩内,露出尾部,从尾尖部取微量血,用超级血糖测试仪测定血糖含量记录血糖值。并统计分析用t检验法比较对照组与模型组之间、各给药组与模型组之间的差异。2.3 Effect of Momordica charantrin on hyperglycemia in streptozotocin-induced diabetic mice: 92 qualified mice (male) were selected, and after feeding for 3 days, 12 mice were taken as the control group, and normal saline was injected intraperitoneally, and the remaining 80 mice were injected intraperitoneally. Streptozotocin 150mg/kg, test the fasting blood glucose content of the mice after 72h, take the mice with blood glucose values between 16-24mmol/L, and divide them into 4 groups according to the blood glucose content (model group, high-dose group, low-dose group) , Jiangtangling group) 12 rats in each group. The high-dose and low-dose groups were given 200 and 100 mg/kg Momordica glucoside by intragastric administration, the Jiangtangling group was given 100 mg/kg Jiangtangling, and the control group and model group were given the same volume of distilled water. Oral gavage once a day, continuous administration 14d. At 3, 7, and 14 days after the administration, the blood sugar content of the mice was tested respectively. The mice were fasted for 12 hours before measuring the blood sugar. During the test, the mice were put into a glass bell jar, and the tail was exposed. The super blood sugar tester measures the blood sugar content and records the blood sugar value. The t test was used to compare the differences between the control group and the model group, and between each administration group and the model group.
2.4苦瓜甾苷对四氧嘧啶所致糖尿病小鼠高血糖的影响:选合格小鼠92只(雄性),饲养3d后,取12只为对照组,腹腔注射生理盐水,其余80只腹腔注射四氧嘧啶220mg/kg,72h后测试小鼠空腹血糖含量,取血糖值在16-24mmol/L之间小鼠,按血糖含量高低分为4组(模型组、大剂量组、小剂量组、降糖灵组)每组12只。大、小剂量组分别灌胃给予苦瓜甾苷200、100mg/kg,降糖灵组给予降糖灵100mg/kg,对照组及模型组给予同体积的蒸馏水。每日灌胃一次,连续给药14d。在给药后3、7、14d时分别测试小鼠血糖含量,小鼠测血糖前禁食12h,测试时把小鼠放入玻璃钟罩内,露出尾部,从尾尖部取微量血,用超级血糖测试仪测定血糖含量记录血糖值。并统计分析用t检验法比较对照组与模型组之间、各给药组与模型组之间的差异。2.4 Effects of Momordica charantrin on hyperglycemia in alloxan-induced diabetic mice: 92 qualified mice (male) were selected, and after feeding for 3 days, 12 mice were taken as a control group, and normal saline was injected intraperitoneally, and the remaining 80 mice were injected four times intraperitoneally. Oxypyrimidine 220mg/kg, test the fasting blood glucose content of the mice after 72h, take the mice with blood glucose values between 16-24mmol/L, and divide them into 4 groups according to the blood glucose levels (model group, high-dose group, small-dose group, Jiangtangling Group) 12 per group. The high-dose and low-dose groups were given 200 and 100 mg/kg Momordica glucoside by intragastric administration, the Jiangtangling group was given 100 mg/kg Jiangtangling, and the control group and model group were given the same volume of distilled water. Oral gavage once a day, continuous administration 14d. At 3, 7, and 14 days after the administration, the blood sugar content of the mice was tested respectively. The mice were fasted for 12 hours before measuring the blood sugar. During the test, the mice were put into a glass bell jar, and the tail was exposed. The super blood sugar tester measures the blood sugar content and records the blood sugar value. The t test was used to compare the differences between the control group and the model group, and between each administration group and the model group.
3结果3 results
3.1 苦瓜甾苷对葡萄糖性小鼠高血糖的影响:小鼠灌胃给予葡萄糖30min后,模型组血糖含量明显升高,灌胃给予苦瓜甾苷大、小剂量组及降糖灵组血糖含量明显低于模型组,在药后60min,降糖率分别为30.2%、28.3%、39.6%,结果见下表。3.1 Effect of Momordica glucoside on hyperglycemia in glucose-induced mice: After intragastric administration of mice with glucose for 30 minutes, the blood sugar level in the model group increased significantly, and the blood sugar level in the large and small dose groups of Momordica glucoside and Jiangtangling group was significantly lower than that in the model group. In the model group, the hypoglycemic rates were 30.2%, 28.3%, and 39.6% at 60 minutes after drug administration, and the results are shown in the table below.
表1-1 苦瓜甾苷对葡萄糖性小鼠高血糖的影响(X±s,n=10)Table 1-1 Effect of Momordica glucoside on hyperglycemia in glucose-induced mice (X±s, n=10)
与模型组比较,*p<0.05,**p<0.01Compared with the model group, *p<0.05, **p<0.01
3.2 苦瓜甾苷对链脲霉素所致糖尿病小鼠高血糖的影响:小鼠腹腔注射链脲霉素72h后,其血糖浓度明显高于对照组。给予苦瓜甾苷200、100mg/kg、连续灌胃14d。在给药3d时测试血糖含量稍有下降,大、小剂量组及降糖灵组的降糖率分别为18.7%、12.5%、25.4%。给药7d时降糖率分别为27.2%、29.8%、28.5%,给药14d时降糖作用显著,降糖率分别为46.5%、41.4%、44.1%。结果表明苦瓜甾苷对链脲霉素所致糖尿病小鼠也具有较好的降血糖作用,结果见下表。3.2 Effect of Momordica charantrin on hyperglycemia in streptozotocin-induced diabetic mice: 72 hours after intraperitoneal injection of streptozotocin, the blood glucose concentration was significantly higher than that in the control group. Give Momordica glucoside 200, 100mg/kg, continuous gavage for 14 days. After 3 days of administration, the test blood sugar content decreased slightly, and the hypoglycemic rates of the large and small dose groups and the Jiangtangling group were 18.7%, 12.5%, and 25.4%, respectively. The hypoglycemic rates were 27.2%, 29.8%, and 28.5% when administered for 7 days, and the hypoglycemic effect was significant when administered for 14 days, and the hypoglycemic rates were 46.5%, 41.4%, and 44.1%. The results showed that Momordica glucuronide also had a good hypoglycemic effect on streptozotocin-induced diabetic mice, and the results are shown in the table below.
表1-2 苦瓜甾苷对链脲霉素所致糖尿病小鼠高血糖的影响(X±s,n=12)Table 1-2 Effect of Momordica glucoside on hyperglycemia in streptozotocin-induced diabetic mice (X±s, n=12)
与对照组比较,ΔΔp<0.01;与模型组比较,*p<0.05,**p<0.01。3.3苦瓜甾苷对四氧嘧啶所致糖尿病小鼠高血糖的影响:小鼠腹腔注射四氧嘧啶72h后,其血糖浓度明显高于对照组。给予苦瓜甾苷200、100mg/kg、连续灌胃14d。在给药3d时测试血糖含量稍有下降,给药7d时降糖率分别为53.5%、33.9%、56.7%,给药14d时降糖作用更为明显,降糖率分别为59.4%、49.3%、60.2%。结果表明苦瓜甾苷对四氧嘧啶所致糖尿病小鼠也具有较好的降血糖作用,结果见下表。Compared with the control group, ΔΔp<0.01; compared with the model group, *p<0.05, **p<0.01. 3.3 Effect of Momordica charantrin on hyperglycemia in alloxan-induced diabetic mice: intraperitoneal injection of alloxan After 72 hours, the blood glucose concentration was significantly higher than that of the control group. Give Momordica glucoside 200, 100mg/kg, continuous gavage for 14 days. After 3 days of administration, the test blood sugar content decreased slightly, and the hypoglycemic rates were 53.5%, 33.9%, and 56.7% respectively at the 7th day of administration. %, 60.2%. The results showed that Momordica glucuronide also has a good hypoglycemic effect on alloxan-induced diabetic mice, and the results are shown in the table below.
表1-3 苦瓜甾苷对四氧嘧啶所致糖尿病小鼠高血糖的影响(X±s,n=12)Table 1-3 Effect of Momordica glycosides on hyperglycemia in alloxan-induced diabetic mice (X±s, n=12)
与对照组比较,ΔΔp<0.01;与模型组比较,**p<0.01。Compared with the control group, ΔΔp<0.01; compared with the model group, **p<0.01.
4 结论4 Conclusion
一小鼠灌服葡萄糖及注射链脲霉素或四氧嘧啶造型后,血糖浓度明显上升,与对照组比较上升率提高了4倍,给药后各给药组与模型组比较,均有不同程度的血糖下降。在小鼠灌服葡萄糖30min时血糖含量明显降低,于模型组比较,大、小剂量及降糖灵组的降糖率分别为30.2%、28.3%、39.6%。在小鼠连续灌胃给药14d后,对链脲霉素所致糖尿病小鼠的降糖作用尤为明显,大、小剂量组及降糖灵组的降糖率分别为46.5%、41.4%、44.1%。对四氧嘧啶所致糖尿病小鼠的降糖作用尤为明显,大、小剂量组及降糖灵组的降糖率分别为59.4%、49.3%、60.2%。从苦瓜甾苷对小鼠降血糖作用的结果表明苦瓜甾苷具有较好的降血糖作用。After a mouse was fed with glucose and injected with streptozotocin or alloxan, the blood sugar concentration increased significantly, and the increase rate increased by 4 times compared with the control group. After administration, each administration group was different from the model group. level of blood sugar drop. When the mice were fed with glucose for 30 minutes, the blood sugar content decreased significantly. Compared with the model group, the hypoglycemic rates of the large and small doses and Jiangtangling group were 30.2%, 28.3%, and 39.6%, respectively. After 14 days of continuous intragastric administration in mice, the hypoglycemic effect on streptozotocin-induced diabetic mice is particularly obvious. The hypoglycemic rates of the large and small dose groups and Jiangtangling group were 46.5%, 41.4%, and 44.1% respectively. . The hypoglycemic effect on alloxan-induced diabetic mice is particularly obvious, and the hypoglycemic rates of the high-dose and low-dose groups and the Jiangtangling group were 59.4%, 49.3%, and 60.2%, respectively. The results of the hypoglycemic effect of Momordica glucoside on mice show that Momordica glucoside has a better hypoglycemic effect.
(二)对正常小鼠和肾上腺素性高血糖小鼠的血糖含量、对四氧嘧啶性糖尿病家兔血糖含量及胰岛素含量的影响(2) Effects on blood sugar levels in normal mice and adrenaline-induced hyperglycemia mice, blood sugar levels and insulin levels in alloxan-induced diabetic rabbits
1仪器与材料:1 Instruments and materials:
1.1.仪器:7230分光光度计(上海分析仪器厂)、80-2离心沉淀器(上海手术器械厂)、可调微量移液管(10-50u1),(上海亚荣生化仪器厂)、可调定量加液器(上海求精玻璃仪器厂)、电热恒温水浴锅(河北黄骅市齐务五金电器厂)。1.1. Instruments: 7230 Spectrophotometer (Shanghai Analytical Instrument Factory), 80-2 Centrifugal Precipitator (Shanghai Surgical Instrument Factory), Adjustable Micropipette (10-50u1), (Shanghai Yarong Biochemical Instrument Factory), can Adjusting volume dosing device (Shanghai Qiujing Glass Instrument Factory), electric heating constant temperature water bath (Hebei Huanghua City Qiwu Hardware Electric Appliance Factory).
1.2 药物:苦瓜提取物,每克相当于71.9克生药,由辽宁省中药现代化工程技术中心,批号:20030506。用蒸馏水配成所需浓度供试验用;糖尿灵片,江西天施康中药股份有限公司生产,批号:20040212;优降糖,北京太洋药业有限公司生产,批号:20030806。降糖灵,山东博山制药有限公司生产,批号:20030815。1.2 Medicine: Bitter melon extract, each gram is equivalent to 71.9 grams of crude drug, produced by Liaoning Provincial Traditional Chinese Medicine Modernization Engineering Technology Center, batch number: 20030506. Distilled water was used to make the required concentration for the test; Tang Niao Ling Tablets, produced by Jiangxi Tianshikang Traditional Chinese Medicine Co., Ltd., batch number: 20040212; glyburide, produced by Beijing Taiyang Pharmaceutical Co., Ltd., batch number: 20030806. Jiangtangling, produced by Shandong Boshan Pharmaceutical Co., Ltd., batch number: 20030815.
1.3试剂:四氧嘧啶,英国Fluka公司生产;肾上腺素,天津氨基酸公司生产;胰岛素放射免疫分析药盒,北京北方生物技术研究所生产。1.3 Reagents: Alloxan, produced by Fluka Company, UK; epinephrine, produced by Tianjin Amino Acid Company; insulin radioimmunoassay kit, produced by Beijing North Biotechnology Research Institute.
1.4动物:小白鼠,昆明种,22-24g,雌雄兼用,由沈阳药科大学实验动物中心提供,合格证号:SCXK(辽)2003-008。日本大耳白家兔,2.7-3.8kg,雄性,由中国医科大学第二临床学院医学实验动物中心提供,合格证号:SCXK(辽)2003-0013。颗粒饲料购于东北第六制药厂饲料分厂。1.4 Animals: White mice, Kunming species, 22-24g, male and female, provided by the Experimental Animal Center of Shenyang Pharmaceutical University, certificate number: SCXK (Liao) 2003-008. Japanese big-eared white rabbits, 2.7-3.8kg, male, provided by the Medical Experimental Animal Center of the Second Clinical College of China Medical University, certificate number: SCXK (Liao) 2003-0013. Pellet feed was purchased from the feed branch of Northeast Sixth Pharmaceutical Factory.
2方法与结果:2 Methods and results:
2.1 苦瓜甾苷的制备:取苦瓜药材,用70%乙醇回流提取3次。合并滤液,通过D-101大孔吸附树脂柱,用水洗至无色,然后用90%乙醇洗脱,收集乙醇洗脱液,脱色,过滤,滤液减压浓缩,得苦瓜甾苷。经比色法测定,苦瓜甾苷的含量为65.2%。2.1 Preparation of Momordica charantia glycosides: take bitter gourd medicinal material, and reflux extraction with 70% ethanol for 3 times. The filtrates were combined, passed through a D-101 macroporous adsorption resin column, washed with water until colorless, and then eluted with 90% ethanol. The ethanol eluate was collected, decolorized, filtered, and the filtrate was concentrated under reduced pressure to obtain Momordica glycosides. As determined by colorimetry, the content of charantrin was 65.2%.
2.2 对正常小鼠血糖含量的影响:取昆明种小鼠60只,雌雄各半,按体重性别随机分为5组,每组12只:空白对照组,等容量水;优降糖组50mg/kg;苦瓜甾苷大剂量组300mg/kg;中剂量组150mg/kg;小剂量组75mg/kg。动物禁食8小时后,自眼眶后静脉丛取血,用葡萄糖氧化酶法测定给药前正常血糖值。取血后即灌胃给药,体积为0.25ml/10g。在给药后2.2 Effects on the blood sugar content of normal mice: Take 60 Kunming mice, half male and half male, and randomly divide them into 5 groups according to body weight and sex, 12 mice in each group: blank control group, equal volume water; glyburide group 50mg/ kg; Momordica glycosides high-dose group 300mg/kg; medium-dose group 150mg/kg; low-dose group 75mg/kg. After the animals were fasted for 8 hours, blood was collected from the retro-orbital venous plexus, and the normoglycemia value before administration was determined by the glucose oxidase method. Immediately after blood collection, intragastric administration was performed, with a volume of 0.25ml/10g. after administration
3、6和9小时取血,测定血糖含量。结果见下表。Blood was collected at 3, 6 and 9 hours to measure blood sugar levels. The results are shown in the table below.
表2-1 对正常小鼠血糖含量的影响(X±SD)Table 2-1 Effects on blood sugar levels in normal mice (X ± SD)
与空白对照组比较 *p<0.05Compared with blank control group *p<0.05
结果表明,苦瓜甾苷对正常小鼠未见明显降低血糖作用,优降糖组在药后3、6小时均有降糖作用,与对照组比较p<0.05。2.3对肾上腺素性高血糖小鼠血糖含量的影响:取小鼠84只,20-22g,雌雄各半,按体重性别随机分为7组,每组12只:空白对照组;模型组;降糖灵组100mg/kg;糖尿灵片组1600mg/kg;苦瓜甾苷大剂量组300mg/kg;中剂量组150mg/kg;小剂量组75mg/kg。动物禁食8小时后取血测血糖值,然后灌胃给药,每天给药1次,连续给药7天。末次药前动物禁食12小时,末药后1小时,腹腔注射肾上腺素240mg/kg(空白对照组除外),30分钟后取血,测血糖值。结果见下表。The results showed that momordica glucoside had no obvious effect on lowering blood sugar in normal mice, and the glyburide group had hypoglycemic effect at 3 and 6 hours after the drug, and compared with the control group, p<0.05. 2.3 For adrenergic hyperglycemia mice Effect of blood sugar content: 84 mice, 20-22g, half male and half female, were randomly divided into 7 groups according to body weight and sex, 12 mice in each group: blank control group; model group; Jiangtangling group 100mg/kg; Tangniailing tablet group 1600mg/kg; Momordica glycosides high-dose group 300mg/kg; medium-dose group 150mg/kg; low-dose group 75mg/kg. After fasting for 8 hours, the animals were fasted for 8 hours to take blood to measure the blood glucose level, and then administered intragastrically, once a day, for 7 consecutive days. Animals were fasted for 12 hours before the last drug, and 1 hour after the last drug, 240 mg/kg of epinephrine was injected intraperitoneally (except for the blank control group), and blood was taken 30 minutes later to measure blood sugar. The results are shown in the table below.
表2-2 对肾上腺素性高血糖小鼠血糖含量的影响 (X±SD)Table 2-2 Effect on blood sugar content of adrenaline hyperglycemia mice (X±SD)
与空白对照组比较 ▲▲p<0.01;与模型组比较 **p<0.01 ▲▲ p<0.01 compared with the blank control group; **p<0.01 compared with the model group
结果表明,苦瓜甾苷对肾上腺素性高血糖小鼠具有明显的降糖作用,其作用强于糖尿灵片。The results showed that Momordica glycosides had obvious hypoglycemic effect on mice with adrenaline hyperglycemia, and its effect was stronger than that of Tangniaoling Tablets.
2.4 对四氧嘧啶引起家兔糖尿病模型的血糖含量和胰岛素水平的影响:取健康雄性家兔80只,体重2.5-3.0kg,禁食32小时后耳缘静脉注射10%四氧嘧啶生理盐水溶液150mg/kg,72小时后耳缘静脉取血测定血糖及胰岛素含量,选造模成功的高血糖家兔60只(14.9-28.8mmol/L),随机分为6组,每组10只,另设空白对照组:即:空白对照组;模型组;降糖灵组80mg/kg;糖尿灵组640mg/kg;苦瓜甾苷大剂量组120mg/kg;中剂量组60mg/kg;小剂量组30mg/kg。每天灌胃给药1次,连续给药7天,于末次药后24小时,动物禁食取血测定血糖及胰岛素含量。结果见下表。2.4 Effects on the blood sugar content and insulin level of the rabbit diabetic model induced by alloxan: take 80 healthy male rabbits, weighing 2.5-3.0kg, and inject 10% alloxan normal saline solution into the ear vein after fasting for 32 hours 150mg/kg, 72 hours later, blood was taken from the ear vein to measure the blood sugar and insulin content, and 60 hyperglycemic rabbits (14.9-28.8mmol/L) with successful modeling were selected and randomly divided into 6 groups, 10 rabbits in each group. Set up a blank control group: namely: blank control group; model group; Jiangtangling group 80mg/kg; Tangguanling group 640mg/kg; Momordica glycosides high-dose group 120mg/kg; medium-dose group 60mg/kg; low-dose group 30mg/kg . The drug was given by intragastric administration once a day for 7 consecutive days, and 24 hours after the last dose, the animals were fasted and blood was taken to measure the blood sugar and insulin levels. The results are shown in the table below.
表2-3 对四氧嘧啶家兔血糖含量和胰岛素水平的影响(X±SD)Table 2-3 Effects on Alloxan Rabbit Blood Glucose Content and Insulin Level (X±SD)
与空白对照组比较▲▲p<0.01;与模型组比较 *p<0.05 **p<0.01Compared with the blank control group ▲▲ p<0.01; compared with the model group *p<0.05 **p<0.01
结果表明,模型组与空白对照组比较差异显著p<0.01,说明造模成功。苦瓜甾苷可明显降低四氧嘧啶性高血糖家兔的血糖值(p<0.05,0.01),具有明显的降糖作用,其作用优于糖尿灵片,但对胰岛素值无明显影响。The results showed that there was a significant difference between the model group and the blank control group, p<0.01, indicating that the model was successfully established. Momordica glucoside can significantly reduce the blood sugar level of rabbits with alloxan-induced hyperglycemia (p<0.05, 0.01), and has obvious hypoglycemic effect, which is better than Tangniaoling Tablets, but has no obvious effect on insulin level.
3结论3 Conclusion
小鼠注射肾上腺素及家兔注射四氧嘧啶造型后,血糖浓度明显上升,与对照组比较有显著性差异,给药后各给药组与模型组比较,均有不同程度的血糖下降。在小鼠连续给药7天后对肾上腺素性糖尿病小鼠血糖明显降低,苦瓜甾苷大、中剂量组降糖率分别为41.6%、37.1%,糖尿灵组为34.9%,其降糖作用优于糖尿灵组。对四氧嘧啶所致糖尿病家兔的降糖作用尤为明显,苦瓜甾苷大、中剂量组降糖率为50.9%、37.4%,降糖作用与降糖灵(54.5%)比较无显著性差异,强于糖尿灵组(40.5%)。以上结果表明:苦瓜甾苷对肾上腺素性高血糖小鼠血糖值有明显降低作用;对四氧嘧啶性糖尿病家兔糖值也有明显降低作用,但对其胰岛素值无明显影响;对正常小鼠血糖值未见明显影响。After mice were injected with adrenaline and rabbits were injected with alloxan modeling, the blood sugar concentration increased significantly, which was significantly different from that of the control group. After administration, each drug group had different degrees of blood sugar drop compared with the model group. After 7 days of continuous administration in mice, the blood sugar of adrenaline diabetic mice was significantly reduced. The hypoglycemic rates of the large and medium dose groups of momordica glycosides were 41.6% and 37.1%, respectively, and that of the Tangniaoling group was 34.9%. Its hypoglycemic effect is better than that of Diabetic group. The hypoglycemic effect on alloxan-induced diabetic rabbits is particularly obvious. The hypoglycemic rates of momordica glycosides in large and medium dose groups are 50.9%, 37.4%, and there is no significant difference in hypoglycemic effect compared with Jiangtangling (54.5%), strong in the Tang Niao Ling group (40.5%). The above results show that: Momordica glucoside significantly reduces the blood sugar level of adrenaline-induced hyperglycemia mice; it also has a significant reduction effect on the sugar level of alloxan-induced diabetes rabbits, but has no significant effect on its insulin value; The value was not significantly affected.
(三)综上所述,苦瓜甾苷对不同原因所致的不同动物模型的高血糖均有一定程度的降糖作用,并且其降糖作用有的与阳性对照药物相当甚至更强。以上的试验证明通过最佳工艺制备的苦瓜总甾苷具有降血糖效果,并且降糖效果比较明显,是苦瓜降糖的有效部位之一。(3) To sum up, Momordica glucoside has a certain degree of hypoglycemic effect on hyperglycemia in different animal models caused by different reasons, and some of its hypoglycemic effects are comparable to or even stronger than positive control drugs. The above experiments prove that the total steroidal glycosides of bitter melon prepared by the optimal process has a hypoglycemic effect, and the hypoglycemic effect is relatively obvious, and it is one of the effective parts of bitter melon for hypoglycemic.
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2007101584965A CN101181336A (en) | 2007-11-26 | 2007-11-26 | A method for refining the effective part of bitter gourd for lowering blood sugar |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2007101584965A CN101181336A (en) | 2007-11-26 | 2007-11-26 | A method for refining the effective part of bitter gourd for lowering blood sugar |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101181336A true CN101181336A (en) | 2008-05-21 |
Family
ID=39446847
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2007101584965A Pending CN101181336A (en) | 2007-11-26 | 2007-11-26 | A method for refining the effective part of bitter gourd for lowering blood sugar |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101181336A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102894364A (en) * | 2012-10-19 | 2013-01-30 | 安徽农业大学 | Preparation method of balsam pear/green tea sugar-reducing buccal tablets |
CN115192623A (en) * | 2022-08-25 | 2022-10-18 | 湖南新有爱农业有限公司 | Process for extracting high-energy lipid-removing essence from mountain balsam pear |
-
2007
- 2007-11-26 CN CNA2007101584965A patent/CN101181336A/en active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102894364A (en) * | 2012-10-19 | 2013-01-30 | 安徽农业大学 | Preparation method of balsam pear/green tea sugar-reducing buccal tablets |
CN115192623A (en) * | 2022-08-25 | 2022-10-18 | 湖南新有爱农业有限公司 | Process for extracting high-energy lipid-removing essence from mountain balsam pear |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100560083C (en) | A preparation method for extracting and purifying total saponins from Chinese medicine Panax notoginseng | |
US9687516B2 (en) | Preparation method for extractive of jinxuan hemorrhoid washing powder botanicals | |
CN102641326A (en) | Membranous milkvetch root extract, as well as preparation and application methods thereof | |
CN103191289B (en) | Synchronous preparation method of four effective parts in medicine pair of common anemarrhena rhizome and amur corktree bark and application thereof | |
CN104840527A (en) | Composition containing tenuifoliside and ginsenoside | |
CN100534508C (en) | Method for extracting effective sites group of smilax China root | |
CN107854507A (en) | A kind of method that flavones ingredient is extracted from folium artemisiae argyi | |
CN107929544B (en) | Preparation method and application of mileanine part and monomer in bletilla plants | |
CN1969945A (en) | Chinese medicinal blood tonic and preparation process thereof | |
CN101919901A (en) | Application of total aglycone of gleditsia sinensis and echinocystic acid in preparation of alpha-glucosidase inhibitor drugs | |
CN1973853B (en) | Hemostatic and analgetic medicine composition and its preparation process | |
CN101040896A (en) | Flavone of astragalus extract, the medicine use and the compound thereof | |
CN101181336A (en) | A method for refining the effective part of bitter gourd for lowering blood sugar | |
CN102579530A (en) | Preparation method of aralia taibaiensis total saponin having diabetes mellitus resisting effect and medicament | |
CN114869923B (en) | Water-soluble extract of ethnic medicine Shuangshen and its preparation method and application | |
CN103417634B (en) | A kind of Ramulus Mori active site and its preparation method and application | |
CN105832814A (en) | General flavone with effect of treating diabetic mellitus, as well as preparation method and application thereof | |
CN102100760A (en) | Plant extract composition capable of preventing and treating sugar metabolism disturbance and preparation method thereof | |
CN100540014C (en) | A kind of plant extract and its preparation method and application | |
CN1814149A (en) | Medicine composition for treating diabetes or diabetes kidney-disease, and preparing method | |
CN101322734B (en) | Total Codonopsis saponins with anti-inflammatory and immune effects and preparation method thereof | |
CN103585226B (en) | A kind of preparation method of Herba Elephantopi Mollis extract and application thereof | |
CN113171412A (en) | Callicarpa nudiflora traditional Chinese medicine composition and preparation method thereof | |
CN102670698B (en) | The application of Radix Flemingiae Philippinensis extract in preparation control diabetes medicament | |
CN102824423B (en) | Medicinal composition comprising albiflorin and arctiin and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20080521 |